Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Ethnopharmacol ; 139(1): 305-10, 2012 Jan 06.
Article in English | MEDLINE | ID: mdl-22120014

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Ge-Gen-Tang (GGT) has been used against adult respiratory tract infection for thousand years in ancient China. However, GGT is unable to inhibit influenza virus. The effect of GGT to manage respiratory tract viral infection has been questioned. Several ingredients of GGT and their constituents are able to inhibit various viruses. Therefore, GGT might have antiviral activity against other viruses causing respiratory tract illness. Human respiratory syncytial virus (HRSV) is one of the most important airway viruses. However, it is unknown whether GGT is effective against HRSV. AIM OF THE STUDY: HRSV contributes considerably to respiratory tract illness of the elderly and immunocompromised adults. There is no effective therapeutic modality for HRSV infection. In order to find a readily available agent to manage HRSV infection, the authors tested the hypothesis that GGT can effectively minimize airway pathology by preventing HRSV-induced plaque formation in respiratory mucosal cell lines. MATERIALS AND METHODS: Effect of the hot water extract of GGT on HRSV was tested by plaque reduction assay in both human upper (HEp-2) and low (A549) respiratory tract cell lines. Ability of GGT to stimulate anti-viral cytokines was evaluated by enzyme-linked immunosorbent assay (ELISA). RESULTS: GGT dose-dependently inhibited HRSV-induced plaque formation in both cell lines (p<0.0001), especially in A549 cells. GGT was more effective when given before viral infection (p<0.0001). GGT could dose-dependently inhibit viral attachment (p<0.0001) with or without heparin. GGT could further inhibit HRSV internalization time-dependently and dose-dependently (p<0.0001). GGT could stimulate mucosal cells to secrete IFN-ß to counteract viral infection before and after viral inoculation. CONCLUSIONS: GGT is effective against HRSV-induced plaque formation in airway epithelium.


Subject(s)
Antiviral Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Respiratory Syncytial Virus, Human/drug effects , Cell Line , Humans , Interferon-beta/metabolism , Respiratory Syncytial Virus, Human/physiology , Tumor Necrosis Factor-alpha/metabolism , Viral Plaque Assay , Virus Attachment/drug effects , Virus Internalization/drug effects
2.
Clin Exp Pharmacol Physiol ; 31(1-2): 65-9, 2004.
Article in English | MEDLINE | ID: mdl-14756686

ABSTRACT

1. The present study was conducted to evaluate the cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents on hepatoma and leukaemia cells in vitro. 2. Four human liver cancer cell lines, namely HepG2, Hep3B, SK-Hep1 and PLC/PRF/5, and four leukaemia cell lines, namely K562, U937, P3H1 and Raji, were used in the present study. 3. Of the two crude drugs, C. chinensis exhibited the strongest activity against SK-Hep1 (IC50 = 7 microg/mL) and Raji (IC50 = 4 microg/mL) cell lines. The IC50 values for C. chinensis on HepG2, Hep3B and PLC/PRF/5 cell lines were 20, 55 and 35 microg/mL, respectively. The IC50 values for C. chinensis on K562, U937 and P3H1 cell lines were 29, 29 and 31 microg/mL, respectively. 4. With the exception of HepG2 and Hep3B, the E. sagittatum extract inhibited the proliferation of all cell lines (SK-Hep1, PLC/PRF/5, K562, U937, P3H1 and Raji), with IC50 values of 15, 57, 74, 221, 40 and 80 microg/mL, respectively. 5. Interestingly, the two major compounds of C. chinensis, berberine and coptisine, showed a strong inhibition on the proliferation of both hepatoma and leukaemia cell lines, with IC50 values varying from 1.4 to 15.2 microg/mL and from 0.6 to 14.1 microg/mL, respectively. However, icariin (the major compound of E. sagittatum) showed no inhibition of either the hepatoma or leukaemia cell lines. 6. The results of the present study suggest that the C. chinensis extract and its major constituents berberine and coptisine possess active antihepatoma and antileukaemia activities.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Berberine/analogs & derivatives , Berberine/pharmacology , Carcinoma, Hepatocellular/drug therapy , Coptis/chemistry , Epimedium/chemistry , Flavonoids/pharmacology , Leukemia, Experimental/drug therapy , Antimetabolites, Antineoplastic/pharmacology , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Fluorouracil/pharmacology , Humans , Leukemia, Experimental/pathology , Plant Extracts/pharmacology , Solutions
3.
Am J Chin Med ; 32(5): 717-25, 2004.
Article in English | MEDLINE | ID: mdl-15633807

ABSTRACT

The water extracts of Cornus officinalis Sieb. et Zuce against hepatocellular carcinoma (HCC) was studied for its chemopreventive potential. Three HCC cell lines (HepG2, SK-Hep1 and PLC/PRF/5) and three leukemic cell lines (U937, K562 and Raji) were tested with XTT assay. Extracts of C. officinalis inhibited all these HCC cells and leukemic cells at a concentration of 100 microg/ml (P < 0.05) and was dose-dependent (P < 0.0001). P53 (P< 0.0001) and Ras (P = 0.001) significantly affected its activity against HCC. Extracts of C. officinalis also possessed the anti-oxidant activity through free radicals scavenging activity at a concentration of 50 microg/ml (P < 0.05). In summary, our experiment implied that C. officinalis might be a candidate for chemopreventive agent against HCC through the antioxidant and anti-neoplastic effects.


Subject(s)
Cell Proliferation/drug effects , Cornus , Drugs, Chinese Herbal/pharmacology , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Humans , K562 Cells , Lipid Peroxidation/drug effects , Liver/drug effects , Liver/metabolism , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , U937 Cells , Xanthine Oxidase/antagonists & inhibitors , Xanthine Oxidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL